Risk of sclerosis in patients with chronic GVHD, according to HLA-DPB1 P1 pocket motifs in donors and recipients
| Genome . | Motif* . | Frequency, no./total (%) . | Unadjusted . | Adjusted† . | ||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| Donor | M∼GPM | 707/808 (88%) | 0.94 (0.61-1.44) | .78 | 0.94 (0.60-1.46) | .77 |
| M∼EAV | 383/808 (47%) | 0.85 (0.64-1.13) | .26 | 0.81 (0.61-1.09) | .16 | |
| Q∼GPM | 220/808 (27%) | 0.71 (0.50-1.00) | .05 | 0.75 (0.53-1.07) | .11 | |
| Q∼EAV | 289/808 (36%) | 0.78 (0.58-1.07) | .12 | 0.81 (0.59-1.11) | .20 | |
| Recipient | M∼GPM | 674/778 (87%) | 1.02 (0.66-1.58) | .94 | 1.01 (0.64-1.60) | .95 |
| M∼EAV | 373/778 (48%) | 0.90 (0.67-1.20) | .47 | 0.85 (0.63-1.15) | .29 | |
| Q∼GPM | 208/778 (27%) | 0.57 (0.39-0.84) | .004 | 0.62 (0.42-0.92) | .02 | |
| Q∼EAV | 281/778 (36%) | 0.74 (0.54-1.02) | .07 | 0.80 (0.57-1.11) | .18 | |
| Genome . | Motif* . | Frequency, no./total (%) . | Unadjusted . | Adjusted† . | ||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| Donor | M∼GPM | 707/808 (88%) | 0.94 (0.61-1.44) | .78 | 0.94 (0.60-1.46) | .77 |
| M∼EAV | 383/808 (47%) | 0.85 (0.64-1.13) | .26 | 0.81 (0.61-1.09) | .16 | |
| Q∼GPM | 220/808 (27%) | 0.71 (0.50-1.00) | .05 | 0.75 (0.53-1.07) | .11 | |
| Q∼EAV | 289/808 (36%) | 0.78 (0.58-1.07) | .12 | 0.81 (0.59-1.11) | .20 | |
| Recipient | M∼GPM | 674/778 (87%) | 1.02 (0.66-1.58) | .94 | 1.01 (0.64-1.60) | .95 |
| M∼EAV | 373/778 (48%) | 0.90 (0.67-1.20) | .47 | 0.85 (0.63-1.15) | .29 | |
| Q∼GPM | 208/778 (27%) | 0.57 (0.39-0.84) | .004 | 0.62 (0.42-0.92) | .02 | |
| Q∼EAV | 281/778 (36%) | 0.74 (0.54-1.02) | .07 | 0.80 (0.57-1.11) | .18 | |
Defined by M (methionine) or Q (glutamine) at position 31 of the HLA-DPα chain and by EAV or GPM motifs at positions 85 to 87 of the HLA-DPβ chain. Presence of the motif was defined by considering HLA-DPα/DPβ heterodimers encoded both in cis and in trans.
Adjusted for stem cell graft source, HLA matching, ABO compatibility, TBI dose, and principal components.